التفاصيل البيبلوغرافية
| العنوان: |
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) |
| المؤلفون: |
Kathleen Dungan, Robert E. Ratner, John B. Buse |
| المصدر: |
Diabetes/metabolism research and reviews. 25(6) |
| سنة النشر: |
2009 |
| مصطلحات موضوعية: |
Blood Glucose, Male, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Pancreatitis-Associated Proteins, Type 2 diabetes, law.invention, Body Mass Index, Endocrinology, Randomized controlled trial, law, Insulin-Secreting Cells, Insulin, C-Peptide, Glutamate Decarboxylase, Fasting, Middle Aged, Treatment Outcome, Area Under Curve, Cytokines, Female, Analysis of variance, Proinsulin, Adult, medicine.medical_specialty, Adolescent, Injections, Subcutaneous, Placebo, Arginine, Young Adult, Double-Blind Method, Antigens, Neoplasm, Internal medicine, Statistical significance, Diabetes mellitus, Internal Medicine, medicine, Biomarkers, Tumor, Humans, Regeneration, Lectins, C-Type, Receptor-Like Protein Tyrosine Phosphatases, Class 8, Adverse effect, Aged, Glycated Hemoglobin, Type 1 diabetes, Analysis of Variance, business.industry, nutritional and metabolic diseases, medicine.disease, Peptide Fragments, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, business |
| الوصف: |
Background Islet neogenesis associated protein (INGAP) has beta cell regenerating effects in experimental models. Methods Subjects with T1DM (N = 63) and T2DM (N = 126) received 300 or 600 mg/day of INGAP peptide in a 90 day, randomized, double-blind, placebo-controlled trial. Results In T1DM, on-treatment Arginine-stimulated C-peptide (AUC0–30) significantly increased from baseline in the 600 mg group (p = 0.0058 versus placebo); no significant changes were seen in the 300 mg group. In T2DM, stimulated C-peptide was significantly better preserved in the 600 mg group compared to placebo at day 120, 30 days after washout (p = 0.031 versus placebo), but did not reach statistical significance during treatment or in the 300 mg group. In T2DM, A1C decreased significantly more in the 600 mg group compared to placebo at day 90 (−0.94% versus −0.47%, respectively, p = 0.009) and day 120, 30 days after washout (−0.73% versus −0.24%, respectively, p = 0.013). This was accompanied by significant reductions in mean glucose. No difference from placebo was detected in the 300 mg group or in T1DM. Injection site reactions were the most common adverse event, occurring in 8 (36%) of placebo, 19 (90%) of 300 mg, and 15 (75%) of 600 mg groups (T1DM) and 14 (33%) of placebo, 27 (64%) of 300 mg, and 29 (69%) of 600 mg groups (T2DM). Conclusions INGAP peptide increases C-peptide secretion in T1DM and improves glycaemic control in T2DM. Longer-term exposure, more frequent dosing, better tolerated formulations or combination with other therapies may be necessary to achieve optimal clinical response. Copyright © 2009 John Wiley & Sons, Ltd. |
| تدمد: |
1520-7560 |
| الوصول الحر: |
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f0944082e3cf7e25cc22e04872e9ffTest
https://pubmed.ncbi.nlm.nih.gov/19626663Test |
| حقوق: |
CLOSED |
| رقم الانضمام: |
edsair.doi.dedup.....16f0944082e3cf7e25cc22e04872e9ff |
| قاعدة البيانات: |
OpenAIRE |
